NcXHF

CATHERINE H. VAN POZNAK
premenopausal patients depending on menstrual status. J Clin Oncol.
2006;24:675-680.
23. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on
bone mineral density measured by dual-energy x-ray absorptiometry in
healthy premenopausal and postmenopausal women. J Clin Oncol.
1996;14:78-84.
24. Eastell R, Hannon R. Long-term effects of aromatase inhibitors on bone.
J Steroid Biochem Mol Biol. 2005;95:151-154.
25. Santen RJ. Clinical Review: effect of endocrine therapies on bone in
breast cancer patients. J Clin Endocrinol Metab. 2011;96:308-319.
26. Body JJ. Prevention and treatment of side-effects of systemic treatment:
bone loss. Ann Oncol. 2010;21 Suppl 7:vii180-vii185.
27. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy
in postmenopausal breast cancer patients: a systematic review and
meta-analysis. J Natl Cancer Inst. 2011;103:1299-1309.
28. Goss PE, Hershman DL, Cheung AM, et al. Effects of adjuvant exemestane
versus anastrozole on bone mineral density for women with early
breast cancer (MA.27B): a companion analysis of a randomised controlled
trial. Lancet Oncol. 2014;15:474-482.
29. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in
healthy postmenopausal women treated with exemestane for the primary
prevention of breast cancer: a nested substudy of the MAP.3 randomised
controlled trial. Lancet Oncol. 2012;13:275-284.
30. Griggs JJ, Somerfıeld MR, Anderson H, et al. American Society of Clinical
Oncology endorsement of the cancer care Ontario practice guideline on
adjuvant ovarian ablation in the treatment of premenopausal women with
early-stage invasive breast cancer. J Clin Oncol. 2011;29:3939-3942.
31. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression
in premenopausal breast cancer. N Engl J Med. 2015;372:436-446.
32. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian
suppression in premenopausal breast cancer. N Engl J Med. 2014;
371:107-118.
33. Genant HK, Cann CE, Ettinger B, et al. Quantitative computed tomography
of vertebral spongiosa: a sensitive method for detecting early bone
loss after oophorectomy. Ann Intern Med. 1982;97:699-705.
34. Sverrisdottir A, Fornander T, Jacobsson H, et al. Bone mineral density
among premenopausal women with early breast cancer in a randomized
trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:3694-3699.
35. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine
therapy plus zoledronic acid in premenopausal women with earlystage
breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral
density substudy. Lancet Oncol. 2008;9:840-849.
36. Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral
density in premenopausal women who develop ovarian failure due
to adjuvant chemotherapy: fınal results from CALGB trial 79809. Eur J
Cancer. 2011;47:683-689.
37. Sweat SD, Pacelli A, Bergstralh EJ, et al. Androgen receptor expression
in prostatic intraepithelial neoplasia and cancer. J Urol. 1999;161:1229-
1232.
38. Schally AV. Luteinizing hormone-releasing hormone analogues and
hormone ablation for prostate cancer: state of the art. BJU Int. 2007;
100:2-4.
39. Smith MR. Osteoporosis during androgen deprivation therapy for prostate
cancer. Urology. 2002;60:79-86.
40. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen
deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
41. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fracture after
gonadotropin-releasing hormone agonist therapy for prostate cancer.
J Urol. 2006;175:136-139.
42. U.S. Prevention Services Task Force. http://www.uspreventiveservices
taskforce.org/uspstopics.htm. Accessed February 04, 2015.
43. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men:
a clinical practice guideline from the American College of Physicians.
Ann Intern Med. 2008;148:680-684.
44. Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients:
ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25 Suppl
3:iii124-iii137.
45. WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/.
Accessed February 04, 2015.
46. Mann GB, Kang YC, Brand C, et al. Secondary causes of low bone mass
in patients with breast cancer: a need for greater vigilance. J Clin Oncol.
2009;27:3605-3610.
47. Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval
and transition to osteoporosis in older women. N Engl J Med. 2012;
366:225-233.
48. Earle CC, Burstein HJ, Winer EP, et al. Quality of non-breast cancer
health maintenance among elderly breast cancer survivors. J Clin Oncol.
2003;21:1447-1451.
49. Snyder CF, Frick KD, Kantsiper ME, et al. Prevention, screening, and
surveillance care for breast cancer survivors compared with controls:
changes from 1998 to 2002. J Clin Oncol. 2009;27:1054-1061.
50. Holt A, Khan MA, Gujja S, et al. Utilization of bone densitometry for
prediction and administration of bisphosphonates to prevent osteoporosis
in patients with prostate cancer without bone metastases receiving
antiandrogen therapy. Cancer Manag Res. 2014;7:13-18.
51. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force report:
bone health in cancer care. J Natl Compr Canc Netw. 2013;11 Suppl
3:S1-S50.
52. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S.
Preventive Services Task Force recommendation statement. Ann Intern
Med. 2011;154:356-364.
53. Nelson HD, Haney EM, Dana T, et al. Screening for osteoporosis: an
update for the U.S. Preventive Services Task Force. Ann Intern Med.
2010;153:99-111.
54. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination
with tamoxifen versus tamoxifen alone for adjuvant treatment of
postmenopausal women with early breast cancer: fırst results of the
ATAC randomised trial [published correction appears in Lancet. 2002;
360:1520]. Lancet. 2002;359:2131-2139.
e574
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook